Related Experiment Video
Updated: Aug 16, 2025
05:50
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
1.3K
Oxidative Stress-Induced Silver Nano-Carriers for Chemotherapy
Minh Phuong Nguyen1, Duy Phong Pham2, Dukjoon Kim1
1School of Chemical Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Pharmaceuticals (Basel, Switzerland)
|December 23, 2022
Summary
This study developed biocompatible polyaspartamide-encapsulated silver nanoparticles (PA-AgNPs) loaded with Doxorubicin (Dox) to enhance cancer cell apoptosis and reduce tumor growth. The novel PA-AgNPs demonstrated significant anti-tumor efficacy and biosafety in vivo.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Silver nanoparticles (AgNPs) show anti-tumor effects via apoptosis induction.
- Enhancing oxidative stress is a strategy to further promote cancer cell apoptosis.
- Targeted drug delivery systems are crucial for effective cancer chemotherapy.
Purpose of the Study:
- To develop and evaluate polyaspartamide-encapsulated silver nanoparticles (PA-AgNPs) carrying Doxorubicin (Dox) for enhanced cancer treatment.
- To investigate the potential of PA-AgNPs to increase oxidative stress and promote apoptosis in cancer cells.
- To assess the in vivo anti-tumor efficacy and biosafety of PA-AgNPs loaded with Dox for chemotherapy.
Main Methods:
- Synthesis and characterization of PA-AgNPs with an average hydrodynamic diameter of 130 nm.
- Conjugation of PA-AgNPs with biotin for enhanced cancer cell targeting.
- Evaluation of Dox release kinetics in cancer environments.
- Assessment of reactive oxygen species generation using DCFDA assay.
- In vitro cytotoxicity testing using MTT assay on 4T1 cancer cells.
- In vivo tumor inhibition and biosafety studies.
Main Results:
- PA-AgNPs demonstrated efficient Dox release (up to 88%) in cancer environments.
- Dox-loaded PA-AgNPs significantly increased reactive oxygen species generation near 4T1 cells.
- In vitro studies confirmed strong inhibition of 4T1 cancer cells by PA-AgNPs with Dox.
- In vivo studies showed significant tumor inhibition, with tumors approximately four times smaller than the control group.
- The developed PA-AgNPs exhibited high biosafety, indicating potential for clinical chemotherapy.
Conclusions:
- Biocompatible PA-AgNPs effectively deliver Doxorubicin, enhancing oxidative stress and apoptosis in cancer cells.
- Biotin-conjugated PA-AgNPs exhibit excellent targeting capabilities and efficient drug release.
- The developed nanocarrier system shows promising in vivo anti-tumor efficacy and high biosafety for chemotherapy applications.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
14.8K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.8K
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K